233 related articles for article (PubMed ID: 16413173)
1. From selective to highly selective SSRIs: a comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram.
Schreiber S; Pick CG
Eur Neuropsychopharmacol; 2006 Aug; 16(6):464-8. PubMed ID: 16413173
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effects of opioid antagonist naloxone on SSRI-induced analgesia and tolerance in mice.
Singh VP; Patil CS; Jain NK; Singh A; Kulkarni SK
Pharmacology; 2003 Nov; 69(3):115-22. PubMed ID: 14512696
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Maurel S; De Vry J; Schreiber R
Alcohol; 1999 Apr; 17(3):195-201. PubMed ID: 10231167
[TBL] [Abstract][Full Text] [Related]
5. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Sánchez C; Meier E
Psychopharmacology (Berl); 1997 Feb; 129(3):197-205. PubMed ID: 9084057
[TBL] [Abstract][Full Text] [Related]
6. Possible involvement of opioidergic systems in the antinociceptive effect of the selective serotonin reuptake inhibitors in sciatic nerve-injured mice.
Nozaki C; Kamei J
Eur J Pharmacol; 2006 Dec; 552(1-3):99-104. PubMed ID: 17056034
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
8. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
11. Are pharmacokinetic drug interactions with the SSRIs an issue?
Brøsen K
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
13. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line.
Hansen CH; Larsen LW; Sørensen AM; Halling-Sørensen B; Styrishave B
Toxicol In Vitro; 2017 Jun; 41():1-11. PubMed ID: 28179152
[TBL] [Abstract][Full Text] [Related]
14. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
Owens MJ; Knight DL; Nemeroff CB
Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
[TBL] [Abstract][Full Text] [Related]
15. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.
Dunham KE; Venton BJ
J Neurochem; 2022 Sep; 162(5):404-416. PubMed ID: 35736504
[TBL] [Abstract][Full Text] [Related]
16. Stimulus properties of fluvoxamine in a conditioned taste aversion procedure.
Gommans J; Bouwknecht JA; Hijzen TH; Berendsen HH; Broekkamp CL; Maes RA; Olivier B
Psychopharmacology (Berl); 1998 Dec; 140(4):496-502. PubMed ID: 9888626
[TBL] [Abstract][Full Text] [Related]
17. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Sánchez C; Gruca P; Papp M
Behav Pharmacol; 2003 Sep; 14(5-6):465-70. PubMed ID: 14501259
[TBL] [Abstract][Full Text] [Related]
18. Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
Nichols AL; Blumenfeld Z; Luebbert L; Knox HJ; Muthusamy AK; Marvin JS; Kim CH; Grant SN; Walton DP; Cohen BN; Hammar R; Looger L; Artursson P; Dougherty DA; Lester HA
J Neurosci; 2023 Mar; 43(13):2222-2241. PubMed ID: 36868853
[TBL] [Abstract][Full Text] [Related]
19. Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.
Millan MJ; Veiga S; Girardon S; Brocco M
Psychopharmacology (Berl); 2003 Aug; 168(4):397-409. PubMed ID: 12721776
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice.
Kamei J; Miyata S; Morita K; Saitoh A; Takeda H
Pharmacol Biochem Behav; 2003 May; 75(2):247-54. PubMed ID: 12873612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
